Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)

Market Cap	14.24B +242.8%
Revenue (ttm)	6.88B +22.5%
Net Income	414.15M -83.5%
EPS	4.84 -86.3%
Shares Out	86.71M
PE Ratio	33.92
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,277,845
Open	154.00
Previous Close	152.11
Day's Range	153.13 - 173.25
52-Week Range	77.55 - 171.82
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	May 28, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 1,246
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INDSWFTLAB

Financial Performance

In fiscal year 2026, Ind-Swift Laboratories's revenue was 6.88 billion, an increase of 22.53% compared to the previous year's 5.62 billion. Earnings were 414.15 million, a decrease of -83.47%.